
The medical landscape for chronic rhinosinusitis is rapidly advancing, with new treatments offering hope for improved quality of life for patients. As pharmaceutical companies race to develop effective therapies, recent clinical trials are shedding light on promising solutions.
Upstream Bio Inc. (NASDAQ:UPB) on Tuesday shared topline results from the Phase 2 VIBRANT trial evaluating verekitug in participants with chronic rhinosinusitis with nasal polyps (CRSwNP).